AstraZeneca and one of its key European suppliers have defended the quality of their Covid-19 vaccine production process after the EU drugs regulator said it was investigating whether there could have been manufacturing defects in specific batches.
阿斯利康(AstraZeneca)及其主要歐洲供應商之一為其新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）疫苗生產過程的質量辯護。此前歐盟藥品監管機構稱其正在調查特定批次的疫苗是否存在制造缺陷。
您已閱讀6%（351字），剩余94%（5623字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。